Advances in management of pediatric chronic immune thrombocytopenia: a narrative review

Abstract

Immune thrombocytopenia (ITP) is a disease in which thrombocytopenia occurs because of immune-mediated platelet destruction and decreased platelet production. Although many pediatric patients with ITP experience spontaneous remission or reach remission within 12 months of first-line therapy, approximately 20% progress to chronic ITP. Patients who do not respond to first-line treatment or experience frequent relapses are of great concern to physicians. This review summarizes recent treatments for second-line treatment of pediatric chronic ITP.

Keywords

• dapsone
• idiopathic thrombocytopenic purpura
• rituximab
• splenectomy
• thrombopoietin